Search This Blog

Thursday, June 11, 2026

Adial acquires Azora Therapeutics, makes ulcerative colitis drug AT177 its new lead program

 


  • Company arranged up to $64 million in concurrent private placement financing tied to the Azora purchase.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)